Can the pharmaceutical industry reduce attrition rates?
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Part of the attrition may be due to low animal-to-human translational success rates; the so-called “translational failure” [3].”
From Animal to human translation: a systematic scoping review of reported concordance rates (2019) · cites this paper as [3]
In the citing paper
“Even so, late-stage attritions are still frequent [11].”
From Cardiovascular disease models: A game changing paradigm in drug discovery and screening (2019) · cites this paper as [11]
In the citing paper
“Inhibition of the hERG channel can be an indicator of the APD prolongation and cardiotoxicity in early stages of drug development [11].”
From Cardiovascular disease models: A game changing paradigm in drug discovery and screening (2019) · cites this paper as [11]
In the citing paper
“Less than 20 years ago, developing a drug took ~12 years, cost under a billion dollars, and the biggest challenges were failures due to efficacy or toxicity-induced attrition2.”
From Exploiting machine learning for end-to-end drug discovery and development (2019) · cites this paper as [2]
Citations
Cites
The price of innovation: new estimates of drug development costs
DiMasi, J. A., Hansen, R. W., & Grabowski, H. G. (2003) · Journal of Health Economics · doi:10.1016/s0167-6296(02)00126-1 · Cited by 4,265 · cited 1×
“In 2001, the costs of discovering and developing a drug were of the order of US d804 millio”
BackgroundRoberds, S. L. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.12.1317 · Cited by 705 · cited 1×
“We have, in a similar manner, provided very strong evidence that inhibition of β-secretase inhibits the production of amyloid-β in knockout mic”
ResultGowen, M., Lazner, F., Dodds, R., Kapadia, R., Feild, J., Tavaria, M., Bertoncello, I., Drake, F., Zavarselk, S., Tellis, I., et al. (1999) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1999.14.10.1654 · Cited by 490
Self-citationMa, P., & Zemmel, R. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd884 · Cited by 174
Booth, B. L., Glassman, R. H., & Ma, P. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1158 · Cited by 84
An animal model for pycnodysostosis: the role of cathepsin K in bone remodelling
Lazner, F., Gowen, M., & Kola, I. (1999) · Molecular Medicine Today · doi:10.1016/s1357-4310(99)01563-4 · Cited by 18 · cited 1×
“and that cathepsin K is involved in bone resorption (further compelling proof of mechanism is provided by humans with pycnodysostosi”
BackgroundSelf-citation2003 approvals: a year of innovation and upward trends
Frantz, S. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1327 · Cited by 15
Research works printed but not linked: 4
- Kola, I. & Rafferty, M. New technologies that may impact drug discovery in the 5–10 year timeframe workshop. 2002 Biomed. Expo Ann Arbor Michigan (data derived from Prous Science, Drugs News Prospect (2002).
- Fearn, C. J. IMS Health. The World Pharmaceutical Market Presented at the Strategic Management Review, Australia, 19–20 June (2002).
- Benjamin, G. A. & Lumley, C. E. Industry Success Rates 2003 Including Trends in Success Rates CMR Report Number 03–202 R (CMR International Surrey, UK, 2003).
- Van den Haak, M. A., Palachandran, J. & Benjamin, G. A. Performance Metrics in Global Pharmaceutical R&D, Company specific review 2002 for Merck & Co. (CMR International, Surrey, UK, 2003).
Cited by
Items 201–300 of 1,025
Use of microdosing to predict pharmacokinetics at the therapeutic dose: Experience with 5 drugs
LAPPIN, G., KUHNZ, W., JOCHEMSEN, R., KNEER, J., CHAUDHARY, A., OOSTERHUIS, B., DRIJFHOUT, W., ROWLAND, M., & GARNER, R. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2006.05.008 · Cited by 241
“p m ( l r H [ a New drugs for the treatment of unmet medical needs re of great importance, but unfortunately, over the past 0 years, development costs have been rising progresively while the number of new drugs receiving mareting approval has fallen to a historically low level.(1,2) he situation has become so serious…”
BackgroundHuchet, Q. A., Kuhn, B., Wagner, B., Kratochwil, N. A., Fischer, H., Kansy, M., Zimmerli, D., Carreira, E. M., & Müller, K. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01455 · Cited by 239
A comprehensive review of UDP-glucuronosyltransferase and esterases for drug development
Oda, S., Fukami, T., Yokoi, T., & Nakajima, M. (2015) · Drug Metabolism and Pharmacokinetics · doi:10.1016/j.dmpk.2014.12.001 · Cited by 232
Zebrafish models for assessing developmental and reproductive toxicity
He, J.-H., Gao, J.-M., Huang, C.-J., & Li, C.-Q. (2014) · Neurotoxicology and Teratology · doi:10.1016/j.ntt.2014.01.006 · Cited by 233
Physicochemical Properties of Pharmaceutical Co-Crystals: A Case Study of Ten AMG 517 Co-Crystals
Stanton, M. K., & Bak, A. (2008) · Crystal Growth & Design · doi:10.1021/cg800173d · Cited by 236
Polypharmacology: The science of multi-targeting molecules
Kabir, A., & Muth, A. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2021.106055 · Cited by 221
McKim Jr., J. (2010) · Combinatorial Chemistry & High Throughput Screening · doi:10.2174/138620710790596736 · Cited by 231
“The evaluation of candidate drugs in animal safety studies should provide a means to verify safety, not identify toxicity.”
BackgroundWang, Y., Sung, C., Dartois, C., Ramchandani, R., Booth, B. P., Rock, E., & Gobburu, J. (2009) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.64 · Cited by 229
“DCb (2) 277 (254, 307) 295 (261, 333) −27 −22 (−71, 24) 1.”
Harris, K., Aylott, M., Cui, Y., Louttit, J. B., McMahon, N. C., & Sridhar, A. (2013) · Toxicological Sciences · doi:10.1093/toxsci/kft113 · Cited by 227
Induced Pluripotent Stem Cells as a Disease Modeling and Drug Screening Platform
Ebert, A. D., Liang, P., & Wu, J. C. (2012) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0b013e318247f642 · Cited by 222
“However, due to the complexity of disease mechanisms in whole organisms, which is poorly reflected by cellular in vitro models, only a few out of the many initially promising small chemicals identified in large-scale chemical in vitro screens qualify for application in humans.(117,120) A major advantage of iPSC-depend…”
BackgroundPrediction of Hepatic Clearance in Human From In Vitro Data for Successful Drug Development
Chiba, M., Ishii, Y., & Sugiyama, Y. (2009) · The AAPS Journal · doi:10.1208/s12248-009-9103-6 · Cited by 228
The Spectrum of Achalasia: Lessons From Studies of Pathophysiology and High-Resolution Manometry
Kahrilas, P. J., & Boeckxstaens, G. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.08.038 · Cited by 235
Shin, S. R., Zhang, Y. S., Kim, D.-J., Manbohi, A., Avci, H., Silvestri, A., Aleman, J., Hu, N., Kilic, T., Keung, W., et al. (2016) · Analytical Chemistry · doi:10.1021/acs.analchem.6b02028 · Cited by 233
Balancing early market access to new drugs with the need for benefit/risk data: a mounting dilemma
Eichler, H.-G., Pignatti, F., Flamion, B., Leufkens, H., & Breckenridge, A. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2664 · Cited by 229
Simulation-Based Approaches for Determining Membrane Permeability of Small Compounds
Lee, C. T., Comer, J., Herndon, C., Leung, N., Pavlova, A., Swift, R. V., Tung, C., Rowley, C. N., Amaro, R. E., Chipot, C., et al. (2016) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.6b00022 · Cited by 230
Garner, J. P. (2014) · ILAR Journal · doi:10.1093/ilar/ilu047 · Cited by 221
Applying Mechanisms of Chemical Toxicity to Predict Drug Safety
Guengerich, F. P., & MacDonald, J. S. (2007) · Chemical Research in Toxicology · doi:10.1021/tx600260a · Cited by 231
Sung, J. H., Esch, M. B., Prot, J.-M., Long, C. J., Smith, A., Hickman, J. J., & Shuler, M. L. (2013) · Lab on a Chip · doi:10.1039/c3lc41017j · Cited by 233
Development of allosteric modulators of GPCRs for treatment of CNS disorders
Nickols, H. H., & Conn, P. J. (2014) · Neurobiology of Disease · doi:10.1016/j.nbd.2013.09.013 · Cited by 226
“drug discovery efforts have been especially challenging and have a very high attrition rate (Kola and Landis, 2004).”
Unimolecular Chemo-fluoro-luminescent Reporter for Crosstalk-Free Duplex Imaging of Hepatotoxicity
Cheng, P., Miao, Q., Li, J., Huang, J., Xie, C., & Pu, K. (2019) · Journal of the American Chemical Society · doi:10.1021/jacs.9b02580 · Cited by 234
Understanding Cryptic Pocket Formation in Protein Targets by Enhanced Sampling Simulations
Oleinikovas, V., Saladino, G., Cossins, B. P., & Gervasio, F. L. (2016) · Journal of the American Chemical Society · doi:10.1021/jacs.6b05425 · Cited by 217
A roadmap for the development of alternative (non-animal) methods for systemic toxicity testing
Basketter, D. (2012) · ALTEX · doi:10.14573/altex.2012.1.003 · Cited by 225
“reduced the attrition percentage for compounds in development in the pharmaceutical industry (Kola and Landis, 2004).”
BackgroundPowley, I. R., Patel, M., Miles, G., Pringle, H., Howells, L., Thomas, A., Kettleborough, C., Bryans, J., Hammonds, T., MacFarlane, M., et al. (2020) · British Journal of Cancer · doi:10.1038/s41416-019-0672-6 · Cited by 218
“Around 60% of new anti-cancer agents fail in RCTs,(2) and the success rate from first-in-human to registration in oncology is ~5% – a figure that is much lower than that for many other diseases.(3,4) The reason for this attrition, despite huge investment, is the subject of much speculation, but key factors include mar…”
BackgroundPredicting antibody developability profiles through early stage discovery screening
Bailly, M., Mieczkowski, C., Juan, V., Metwally, E., Tomazela, D., Baker, J., Uchida, M., Kofman, E., Raoufi, F., Motlagh, S., et al. (2020) · mAbs · doi:10.1080/19420862.2020.1743053 · Cited by 228
PROMISCUOUS: a database for network-based drug-repositioning
von Eichborn, J., Murgueitio, M. S., Dunkel, M., Koerner, S., Bourne, P. E., & Preissner, R. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkq1037 · Cited by 225
“(4) To establish a clear view of the network the user is able to manipulate the display style of the nodes, to fix the view, zoom in and out and to alter the spring constant of the edges.”
BackgroundHarvey, A. L. (2014) · Toxicon · doi:10.1016/j.toxicon.2014.10.020 · Cited by 210
Evans, E. K., Tester, R., Aslanian, S., Karp, R., Sheets, M., Labenski, M. T., Witowski, S. R., Lounsbury, H., Chaturvedi, P., Mazdiyasni, H., et al. (2013) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.113.203489 · Cited by 220
“Discussion Recent analysis suggests that attrition rates in clinical development are highest in Phase 2 clinical trials, where lack of PD activity and/or efficacy leads to failure rates of approximately a third of drug candidates (Kola and Landis, 2004).”
BackgroundThe Significance of G Protein-Coupled Receptor Crystallography for Drug Discovery
Salon, J. A., Lodowski, D. T., & Palczewski, K. (2011) · Pharmacological Reviews · doi:10.1124/pr.110.003350 · Cited by 222
“12) (Kola and Landis, 2004).”
Pfefferle, A. D., Herschkowitz, J. I., Usary, J., Harrell, J. C., Spike, B. T., Adams, J. R., Torres-Arzayus, M. I., Brown, M., Egan, S. E., Wahl, G. M., et al. (2013) · Genome Biology · doi:10.1186/gb-2013-14-11-r125 · Cited by 224
“Currently, only approximately 5% of oncology drugs that enter clinical testing are ultimately approved by the US Food and Drug Administration for use [4].”
Organs-on-a-chip: a new tool for drug discovery
Polini, A., Prodanov, L., Bhise, N. S., Manoharan, V., Dokmeci, M. R., & Khademhosseini, A. (2014) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2014.886562 · Cited by 223
“In vivo toxicity is one of the major reasons for the failure of » 90% of the drugs after costly Phase I clinical trials [21,22].”
BackgroundVan Norman, G. A. (2016) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2016.06.003 · Cited by 223
“Almost one-half of drugs fail in Phase III clinical trials due to safety and efficacy concerns (66,67).”
BackgroundCardiovascular disease models: A game changing paradigm in drug discovery and screening
Savoji, H., Mohammadi, M. H., Rafatian, N., Toroghi, M. K., Wang, E. Y., Zhao, Y., Korolj, A., Ahadian, S., & Radisic, M. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2018.09.036 · Cited by 223
Machine learning in preclinical drug discovery
Catacutan, D. B., Alexander, J., Arnold, A., & Stokes, J. M. (2024) · Nature Chemical Biology · doi:10.1038/s41589-024-01679-1 · Cited by 204
“From the 1990s to 2017, the proportion of drug candidates that failed clinical trials due to poor drug-like properties decreased from 30–40% to 10–15% 87,88 .”
Metabolism and Toxicity of Drugs. Two Decades of Progress in Industrial Drug Metabolism
Baillie, T. A. (2008) · Chemical Research in Toxicology · doi:10.1021/tx7002273 · Cited by 218
Sacks, L. V., Shamsuddin, H. H., Yasinskaya, Y. I., Bouri, K., Lanthier, M. L., & Sherman, R. E. (2014) · JAMA · doi:10.1001/jama.2013.282542 · Cited by 214
“6 We grouped the deficiencies into 4 primary categories: (1) efficacy; (2) safety; (3) chemistry, manufacturing, and controls (CMC); and (4) product labeling.”
BackgroundInsights into the success and failure of systemic therapy for hepatocellular carcinoma
Bruix, J., da Fonseca, L. G., & Reig, M. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0179-x · Cited by 220
Chesi, M., Matthews, G. M., Garbitt, V. M., Palmer, S. E., Shortt, J., Lefebure, M., Stewart, A. K., Johnstone, R. W., & Bergsagel, P. L. (2012) · Blood · doi:10.1182/blood-2012-02-412783 · Cited by 214
Computer-aided drug design: the next 20 years
Van Drie, J. H. (2007) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-007-9142-y · Cited by 206
Ferri, N., Siegl, P., Corsini, A., Herrmann, J., Lerman, A., & Benghozi, R. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.03.005 · Cited by 205
Compressing drug development timelines in oncology using phase '0' trials
Kummar, S., Kinders, R., Rubinstein, L., Parchment, R. E., Murgo, A. J., Collins, J., Pickeral, O., Low, J., Steinberg, S. M., Gutierrez, M., et al. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2066 · Cited by 213
Pharmacokinetics in Drug Discovery
Ruiz-Garcia, A., Bermejo, M., Moss, A., & Casabo, V. G. (2008) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21009 · Cited by 199
Drug Safety Sciences and the Bottleneck in Drug Development
Watkins, P. B. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.63 · Cited by 211
Improvement in ADMET Prediction with Multitask Deep Featurization
Feinberg, E. N., Joshi, E., Pande, V. S., & Cheng, A. C. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b02187 · Cited by 202
Is animal research sufficiently evidence based to be a cornerstone of biomedical research?
Pound, P., & Bracken, M. B. (2014) · BMJ · doi:10.1136/bmj.g3387 · Cited by 207
Mathias, A. A., German, P., Murray, B. P., Wei, L., Jain, A., West, S., Warren, D., Hui, J., & Kearney, B. P. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.228 · Cited by 205
A role for fMRI in optimizing CNS drug development
Borsook, D., Becerra, L., & Hargreaves, R. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2027 · Cited by 203
Use of precision cut lung slices as a translational model for the study of lung biology
Liu, G., Betts, C., Cunoosamy, D. M., Åberg, P. M., Hornberg, J. J., Sivars, K. B., & Cohen, T. S. (2019) · Respiratory Research · doi:10.1186/s12931-019-1131-x · Cited by 206
Clinical Approval Success Rates for Investigational Cancer Drugs
DiMasi, J. A., Reichert, J. M., Feldman, L., & Malins, A. (2013) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2013.117 · Cited by 203
The multifactorial role of the 3Rs in shifting the harm-benefit analysis in animal models of disease
Graham, M. L., & Prescott, M. J. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.03.040 · Cited by 195
Ivy, S. P., Siu, L. L., Garrett-Mayer, E., & Rubinstein, L. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1961 · Cited by 199
“However, the high attrition rates in oncologic therapeutics have generated tremendous pressures to identify promising drug candidates early on and expedite their advancement, while abandoning those drugs with little hope of ever achieving regulatory approvals (30).”
BackgroundHigh-Throughput Methods for Combinatorial Drug Discovery
Sun, X., Vilar, S., & Tatonetti, N. P. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006667 · Cited by 197
“5, 338 (2009).”
Cardiovascular Drug Development
Fordyce, C. B., Roe, M. T., Ahmad, T., Libby, P., Borer, J. S., Hiatt, W. R., Bristow, M. R., Packer, M., Wasserman, S. M., Braunstein, N., et al. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.03.016 · Cited by 202
Research for new drugs for elimination of onchocerciasis in Africa
Kuesel, A. C. (2016) · International Journal for Parasitology: Drugs and Drug Resistance · doi:10.1016/j.ijpddr.2016.04.002 · Cited by 201
Astashkina, A., & Grainger, D. W. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.02.008 · Cited by 195
A Validated Tumorgraft Model Reveals Activity of Dovitinib Against Renal Cell Carcinoma
Sivanand, S., Peña-Llopis, S., Zhao, H., Kucejova, B., Spence, P., Pavia-Jimenez, A., Yamasaki, T., McBride, D. J., Gillen, J., Wolff, N. C., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003643 · Cited by 193
“Food and Drug Administration (FDA) approval (1–3), twice the failure rate of drugs in other categories (1).”
Clearance in Drug Design: Miniperspective
Smith, D. A., Beaumont, K., Maurer, T. S., & Di, L. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01263 · Cited by 177
Chemokine-Directed Tumor Microenvironment Modulation in Cancer Immunotherapy
Bule, P., Aguiar, S. I., Aires-Da-Silva, F., & Dias, J. N. R. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22189804 · Cited by 185
Improving the translation of analgesic drugs to the clinic: animal models of neuropathic pain
Percie du Sert, N., & Rice, A. S. C. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12645 · Cited by 188
“Additionally, an analysis of the success rate from first-in-man to registration during the period 1991–2000 across therapeutic areas shows that the level of attrition was very high, with a success rate of only 11%, meaning that only one in nine compounds were approved (Kola and Landis, 2004).”
BackgroundMethodQuantitative-qualitative data acquisition using a benchtop orbitrap mass spectrometer
Bateman, K. P., Kellmann, M., Muenster, H., Papp, R., & Taylor, L. (2009) · Journal of the American Society for Mass Spectrometry · doi:10.1016/j.jasms.2009.03.002 · Cited by 192
“The widespread adoption of triple-quadrupole mass spectrometers for quantitative analysis in the pharmaceutical industry has been a major contributing factor to the reduced attrition ascribed to poor pharmacokinetic properties [1, 2].”
BackgroundMathias, N. R., & Hussain, M. A. (2010) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21793 · Cited by 182
Buckton, L. K., Rahimi, M. N., & McAlpine, S. R. (2021) · Chemistry – A European Journal · doi:10.1002/chem.201905385 · Cited by 190
Expanding control of the tumor cell cycle with a CDK2/4/6 inhibitor
Freeman-Cook, K., Hoffman, R. L., Miller, N., Almaden, J., Chionis, J., Zhang, Q., Eisele, K., Liu, C., Zhang, C., Huser, N., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.08.009 · Cited by 189
Smith, A. J. T., Zhang, X., Leach, A. G., & Houk, K. N. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm800498e · Cited by 193
Workman, P., Aboagye, E. O., Chung, Y.-L., Griffiths, J. R., Hart, R., Leach, M. O., Maxwell, R. J., McSheehy, P. M. J., Price, P. M., & Zweit, J. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj162 · Cited by 188
The oxidative stress theory of disease: levels of evidence and epistemological aspects
Ghezzi, P., Jaquet, V., Marcucci, F., & Schmidt, H. H. H. W. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13544 · Cited by 180
“For instance, all thiol-based antioxidants, such as GSH, are also reducing agents and will not only scavenge free radicals but will also reduce labile disulfides (Kim et al., 2001; Laragione et al., 2003).”
Development of Safe Drugs: The hERG Challenge
Kalyaanamoorthy, S., & Barakat, K. H. (2018) · Medicinal Research Reviews · doi:10.1002/med.21445 · Cited by 174
“eReprinted from Toxicology Letters, 230 (3), Anwar Anwar-Mohamed, Khaled H.”
BackgroundMicrofluidic 3D models of cancer
Sung, K. E., & Beebe, D. J. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.07.002 · Cited by 190
“The success rate for oncology drugs is more than three times lower than drugs for cardiovascular disease[85,88].”
BackgroundThe Japanese toxicogenomics project: Application of toxicogenomics
Uehara, T., Ono, A., Maruyama, T., Kato, I., Yamada, H., Ohno, Y., & Urushidani, T. (2010) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.200900169 · Cited by 187
“Even with this advantage, many candidate drugs have been eliminated because of toxicity that could not be found in preclinical tests in the early stage of drug development; rather, the toxicity became apparent at the later stage of drug development, such as during long-term toxicity studies for animal models and after…”
BackgroundKell, D. B., Dobson, P. D., & Oliver, S. G. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2011.05.010 · Cited by 186
Wang, L., You, Z.-H., Chen, X., Xia, S.-X., Liu, F., Yan, X., Zhou, Y., & Song, K.-J. (2018) · Journal of Computational Biology · doi:10.1089/cmb.2017.0135 · Cited by 188
“Although much progress has been made over the past few decades, drug discovery remains a long and expensive process (Dickson and Gagnon, 2004; Kola and Landis, 2004; Paul et al., 2010).”
Predictive validity of behavioural animal models for chronic pain
Berge, O. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01300.x · Cited by 173
“Lack of efficacy has been estimated to be the cause of about 30% of failures in clinical phase of drug development (Kola and Landis, 2004), and several potential analgesics have failed in clinical trials over the last two decades.”
BackgroundNowak-Sliwinska, P., Scapozza, L., & Ruiz i Altaba, A. (2019) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2019.04.005 · Cited by 183
“nently the human phenotype and thus, are less predictive of the patient situation [30].”
BackgroundInfluentialTarget–drug interactions: first principles and their application to drug discovery
Núñez, S., Venhorst, J., & Kruse, C. G. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2011.06.013 · Cited by 181
Shah, M. A., Jhawer, M., Ilson, D. H., Lefkowitz, R. A., Robinson, E., Capanu, M., & Kelsen, D. P. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.0770 · Cited by 186
“As many as 60% of positive phase II findings are not validated in phase III trials.(33,34) However, in view of continued compelling phase II data, “Is bevacizumab with chemotherapy still worth examining in gastroesophageal malignancies?” Although the AVAGAST study did not demonstrate an OS advantage for bevacizumab wi…”
BackgroundAddressing toxicity risk when designing and selecting compounds in early drug discovery
Segall, M. D., & Barber, C. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2014.01.006 · Cited by 171
The application of cell‐based label‐free technology in drug discovery
Xi, B., Yu, N., Wang, X., Xu, X., & Abassi, Y. (2008) · Biotechnology Journal · doi:10.1002/biot.200800020 · Cited by 184
“On the other hand, drug discovery continues to be a risky endeavor and thus far, these advances have not yet translated into blockbuster drugs that were once envisioned [1].”
BackgroundAnimal testing and its alternatives—the most important omics is economics
Meigs, L. (2018) · ALTEX · doi:10.14573/altex.1807041 · Cited by 184
An analysis of the use of animal models in predicting human toxicology and drug safety
Bailey, J., Thew, M., & Balls, M. (2014) · Alternatives to Laboratory Animals · doi:10.1177/026119291404200306 · Cited by 182
Esch, M. B., Sung, J. H., Yang, J., Yu, C., Yu, J., March, J. C., & Shuler, M. L. (2012) · Biomedical Microdevices · doi:10.1007/s10544-012-9669-0 · Cited by 179
“Low bioavailability of drugs at the target organ has been cited as one of the major reasons for the failure of newly developed drugs in clinical trials (Kola and Landis 2004).”
Ribba, B., Holford, N., Magni, P., Trocóniz, I., Gueorguieva, I., Girard, P., Sarr, C., Elishmereni, M., Kloft, C., & Friberg, L. (2014) · CPT: Pharmacometrics & Systems Pharmacology · doi:10.1038/psp.2014.12 · Cited by 173
Boyd, N. K., Teng, C., & Frei, C. R. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.684515 · Cited by 197
“Poor absorption was a major source of attrition during drug discovery in the early 1990s (Kola and Landis, 2004).”
BackgroundEnhancing preclinical drug discovery with artificial intelligence
Vijayan, R. S. K., Kihlberg, J., Cross, J. B., & Poongavanam, V. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2021.11.023 · Cited by 180
“117 121 In addition, the establishment of miniaturized, high-throughput in vitro ADMET pro fi ling assays resulted in the parallel evaluation of ef fi cacy and ADMET during earlier stages of drug discovery.”
MethodKu, M. S., & Dulin, W. (2012) · Pharmaceutical Development and Technology · doi:10.3109/10837450.2010.535826 · Cited by 172
“Phase 1 and POC strategies The Quick-to-Clinic strategy has developed based on statistics showing that over a 10-year period ending in 2000 only approximately 11% of compounds tested in humans by 10 large pharmaceutical companies were eventually approved for marketing in the United States and/or Europe.”
BackgroundInfluentialKarrison, T. G., Maitland, M. L., Stadler, W. M., & Ratain, M. J. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djm158 · Cited by 177
Assessing cognitive function in clinical trials of schizophrenia
Barnett, J. H., Robbins, T. W., Leeson, V. C., Sahakian, B. J., Joyce, E. M., & Blackwell, A. D. (2010) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2010.01.012 · Cited by 174
“CNS drugs have one of the lowest success rate of any therapeutic area, take longer to develop, and tend to fail at later stages, mainly due to inefficacy (Kola and Landis, 2004).”
BackgroundRosfjord, E., Lucas, J., Li, G., & Gerber, H.-P. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.06.008 · Cited by 177
“Retrospective analysis of the success rates of cancer drugs from first-in-man studies to registration, range from 5% to 20% [1,2].”
BackgroundAyurvedic research and methodology: Present status and future strategies
Semwal, D., Chauhan, A., Mishra, S., & Semwal, R. (2015) · AYU (An international quarterly journal of research in Ayurveda) · doi:10.4103/0974-8520.190699 · Cited by 160
“Various previous studies on piperine revealed that its combination improves the bioavailability of synthetic drugs such as propranolol, theophylline, and rifampicin.[16]”
BackgroundCheng, D., Xu, W., Yuan, L., & Zhang, X. (2017) · Analytical Chemistry · doi:10.1021/acs.analchem.7b01671 · Cited by 177
Modeling Promiscuity Based on in vitro Safety Pharmacology Profiling Data
Azzaoui, K., Hamon, J., Faller, B., Whitebread, S., Jacoby, E., Bender, A., Jenkins, J. L., & Urban, L. (2007) · ChemMedChem · doi:10.1002/cmdc.200700036 · Cited by 176
Application of Permeation Enhancers in Oral Delivery of Macromolecules: An Update
Maher, S., Brayden, D. J., Casettari, L., & Illum, L. (2019) · Pharmaceutics · doi:10.3390/pharmaceutics11010041 · Cited by 163
Engineering Tumors: A Tissue Engineering Perspective in Cancer Biology
Burdett, E., Kasper, F. K., Mikos, A. G., & Ludwig, J. A. (2010) · Tissue Engineering Part B: Reviews · doi:10.1089/ten.teb.2009.0676 · Cited by 172
“9 This represents a huge burden, both financially and clinically, as limited resources are often devoted to compounds that will never demonstrate clinical benefit.”
Multi-Parameter Optimization: Identifying High Quality Compounds with a Balance of Properties
D. Segall, M. (2012) · Current Pharmaceutical Design · doi:10.2174/138161212799436430 · Cited by 172
Stability of IgG isotypes in serum
Correia, I. (2010) · mAbs · doi:10.4161/mabs.2.3.11788 · Cited by 172
Kell, D. B., & Goodacre, R. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2013.07.014 · Cited by 169
UNC2025, a Potent and Orally Bioavailable MER/FLT3 Dual Inhibitor
Zhang, W., DeRyckere, D., Hunter, D., Liu, J., Stashko, M. A., Minson, K. A., Cummings, C. T., Lee, M., Glaros, T. G., Newton, D. L., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500749d · Cited by 164
Developing Structure−Activity Relationships for the Prediction of Hepatotoxicity
Greene, N., Fisk, L., Naven, R. T., Note, R. R., Patel, M. L., & Pelletier, D. J. (2010) · Chemical Research in Toxicology · doi:10.1021/tx1000865 · Cited by 171
Nanoparticle Therapeutics: FDA Approval, Clinical Trials, Regulatory Pathways, and Case Study
Eifler, A. C., & Thaxton, C. S. (2011) · Methods in Molecular Biology · doi:10.1007/978-1-61779-052-2_21 · Cited by 168
Mining genomes and ‘metagenomes’ for novel catalysts
Ferrer, M., Martínez-Abarca, F., & Golyshin, P. N. (2005) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2005.09.001 · Cited by 173
Biomarker-Driven Early Clinical Trials in Oncology: A Paradigm Shift in Drug Development
Tan, D. S. W., Thomas, G. V., Garrett, M. D., Banerji, U., de Bono, J. S., Kaye, S. B., & Workman, P. (2009) · The Cancer Journal · doi:10.1097/ppo.0b013e3181bd0445 · Cited by 171
Sydes, M. R., Parmar, M. K., Mason, M. D., Clarke, N. W., Amos, C., Anderson, J., de Bono, J., Dearnaley, D. P., Dwyer, J., Green, C., et al. (2012) · Trials · doi:10.1186/1745-6215-13-168 · Cited by 174
“A large proportion of agents are unsuccessful in phase III trials [11-13], so it can be reasonably anticipated that accrual to at least one research arm in a MAMS trial is likely to be stopped early.”
Background
Metadata
- Authors
- Kola, I., & Landis, J.
- Affiliations
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Corresponding author
- Kola, Ismail
- ORCID
- Landis, John
- Venue
- Nature Reviews Drug Discovery
- Published
- 2004-08
- Volume
- 3
- Issue
- 8
- Pages
- 711-716
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W1895993106
- Cited by
- 4,167
- References
- 7
- Citations by year
- 2026: 121 · 2025: 129 · 2024: 126 · 2023: 159 · 2022: 165 · 2021: 188 · 2020: 179 · 2019: 203 · 2018: 183 · 2017: 194 · 2016: 256 · 2015: 294 · 2014: 279 · 2013: 307 · 2012: 300
- FWCI
- 199.36
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Health Sciences › Nursing › Issues, ethics and legal aspects › Pharmaceutical industry and healthcare
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Health and Medical Research Impacts
- Keywords
- pharmaceutical industry, attrition rates, R&D productivity, drug development costs, health care cost containment, drug costs, R&D investment
- MeSH terms
- Clinical Trials as Topic, Drug Industry, Humans, Pharmacokinetics, Drug Design, Drug Approval
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.